SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.72-4.4%3:26 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tharos who wrote (4232)10/22/1997 5:13:00 PM
From: Andrew H  Read Replies (2) of 17367
 
Thanks for the explanation Tharos. I am still not sure what you mean by "conclusive results from FDA," in light of your explanation. Do you mean something like approval from the advisory panel after completion of P3 for meningo? Surely they won't wait to partner hem trauma indication till then, will they. Don't they need a partner to finance P3 hem trauma trials? Don't they want to begin hem trauma trials sooner than later, or are you saying, no they don't?

Apologize if I am being dense here. Appreciate your clarifications.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News